Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

July 10, 2009 Approval Letter - FluLaval

July 10, 2009

Our STN:  BL 125163/125                

GlaxoSmithKline Biologicals

Attention:  Mary Beth Ebert, M.S.

2301 Renaissance Boulevard
Building 510, P.O. Box 61540
King of Prussia, PA 19406-2772

Dear Ms. Ebert:

We have approved your request to supplement your biologics license application for Influenza Virus Vaccine, FluLaval®, to include the 2009-2010 United States formulation.

Please submit final printed labeling at the time of use and include completed implementation information on FDA form 356h.  Please provide PDF-format electronic copies of these labels. 

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

Jerry P. Weir, Ph.D.
Division of Viral Products
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research

Attachment: Approved final draft labeling

Resources for You

Page Last Updated: 07/20/2009
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.